Histakut

Histakut is a pharmaceutical product that contains the active ingredient dimetindene maleate. It is supplied as an intravenous preparation, with the specific strength not disclosed in the available data. Marketed in the European Union, Histakut belongs to the antihistamine drug class and is used for its antiallergic properties. The formulation is intended for administration by a healthcare professional and should be stored according to the manufacturer’s guidelines.

Histakut is indicated for the management of several histamine‑mediated allergic conditions.

- Relief of symptoms associated with allergic rhinitis, such as nasal congestion, sneezing, and itching. - Treatment of acute urticaria (hives) to reduce wheal formation and itching. - Control of pruritus related to dermatologic disorders. - Adjunct therapy for other allergic reactions where H1 blockade is desired. - Use in patients where an intravenous antihistamine is preferred due to severity or inability to take oral medication.

Like other antihistamines, dimetindene may cause a range of adverse reactions, most of which are mild and reversible.

Common: - Drowsiness or mild sedation. - Dry mouth or throat. - Headache. - Nausea or mild gastrointestinal discomfort.

Serious: - Tachycardia or irregular heart rhythm. - Severe hypotension. - Allergic skin reactions such as rash or angio‑edema. - Acute urinary retention in susceptible individuals.

When prescribing or administering Histakut, healthcare professionals should evaluate patient history and clinical status to minimize risk.

- Assess for known hypersensitivity to dimetindene or other antihistamines. - Use caution in patients with cardiovascular disease, arrhythmias, or uncontrolled hypertension. - Evaluate renal or hepatic impairment, as drug clearance may be altered. - Consider potential anticholinergic effects in the elderly or those with glaucoma, prostatic hypertrophy, or urinary retention. - Avoid use during pregnancy or lactation unless the benefit outweighs potential risk. - Monitor for excessive sedation if combined with other central nervous system depressants.

Dimetindene can interact with other medications, influencing its efficacy or safety profile.

Avoid: - Concomitant use with other potent H1 antagonists may increase sedation and anticholinergic burden. - Co‑administration with monoamine oxidase inhibitors (MAOIs) may potentiate cardiovascular effects.

Use with caution: - Concurrent CNS depressants such as benzodiazepines, opioids, or alcohol may enhance drowsiness. - Beta‑blockers may reduce the effectiveness of antihistamine treatment in anaphylaxis. - Drugs that prolong QT interval should be used cautiously due to additive cardiac risk. - Anticholinergic agents may exacerbate dry mouth, constipation, or urinary retention.